

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 13 2002

TECH CENTER 1600/2900

Applicant: Charles L. Sawyers et al.
Serial No.: 10/067,705
Filed: February 4, 2002
Docket: 30435.53USD7
Title: PURIFIED HUMAN PROSTATE CANCER CELLS

COPY OF PAPERS
ORIGINALLY FILED

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this paper or fee is being deposited with the United States Postal as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on April 30, 2002.

By: 
Name: Richele Ann Domingo

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.8.
- ☒ Information Disclosure Statement (37 C.F.R. §1.97 (d))
- ☒ Form 1449 (Information Disclosure Statement)
- ☒ Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO

35 No. Arroyo Parkway, Suite 60
Pasadena, California 91103
(626)395-7801

By: 
Name: Sarah B. Adriano
Reg. No.: 34,470
Initials: SBA



COPY OF PAPERS
ORIGINALY FILED

RECEIVED

MAY 13 2002


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicant: Charles L. Sawyers, et al. **Examiner:** Not yet assigned
Serial No.: 10/067,705 **Group Art Unit:** 1632
Filed: February 4, 2002 **Docket No.:** 30435.53USD7
Title: PURIFIED HUMAN PROSTATE CANCER CELLS

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on April 30, 2002.

By: 
Richelle Ann Domingo

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(d))

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. They are as follows:

- Liu, A.Y., et al., "Prostatic Cell Lineage Markers: Emergence of BCL2⁺ Cells of Human Prostate Cancer Xenograft LuCaP 23 Following Castration," *Int. J. Cancer*, 65:85-89 (1996).
- Lubaroff, D.M., et al., "Survival of Human Prostate Carcinoma, Benign Hyperplastic Prostate Tissues, and IL-2 Activated Lymphocytes in SCID Mice," *The Prostate*, 27:32-41 (1995).
- Wainstein, M.A., et al., "CWR22: Androgen-Dependent Xenograft Model Derived from a Primary Human Prostatic Carcinoma," *Cancer Research*, 54:6049-6052 (1994).
- Pretlow, T.G., et al., "Xenograft of Primary Human Prostatic Carcinoma," *Journal of the National Cancer Institute*, 85(5):394-398 (1993).

- Pretlow, T.G., et al., "Transplantation of Human Prostatic Carcinoma into Nude Mice in Matrigel," *Cancer Research*, 51:3814-3817 (1991).
- Perez-Stable, et al., *Cancer Research*, Vol. 57, Pages 900-906. (March 1, 1997).
- Sato, et al., *Journal of Urology*, Vol. 155: 5, Page 338A (May 4, 1996).
- van Weerden, et al., *American Journal of Pathology*, Vol. 149: 3, Pages 1055-1062. (September 1996).

This statement should be considered because it is submitted before the mailing date of the first Office Action on the merits. The present application is a divisional application of U.S. Serial No. 09/567,202, filed May 8, 2000. The art cited in the enclosed PTO Form 1449 were previously of record in the parent application, i.e., U. S. Serial No. 09/567, 202 and are not provided herewith in accordance with 37 C.F.R. §1.98(d).

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

No fees are due in connection with the filing of this IDS. If, however, a fee is deemed necessary, please charge any additional fees to Deposit Account No. 50-0306.

Respectfully submitted,

Sarah B. Adriano

Sarah B. Adriano
Registration No. 34,470
Attorney for Applicants
Mandel & Adriano
35 N. Arroyo Parkway, Suite 60
Pasadena, CA 91103
(626) 395-7801

INFORMATION DISCLOSURE STATEMENT

Application Number

09/567, 202

Applicant

(Use several sheets if necessary)

Filing Date

Group Art Unit

May 8, 2000

1632

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

TNT

Liu, A. Y., et al., "Prostatic Cell Lineage Markers: Emergence of BCL2⁺ Cells of Human Prostate Cancer Xenograft LuCaP 23 Following Castration," *Int. J. Cancer*, 65:85-89 (1996).

Lubaroff, D. M., et al., "Survival of Human Prostate Carcinoma, Benign Hyperplastic Prostate Tissues, and IL-2-Activated Lymphocytes in SCID Mice," *The Prostate*, 27:32-41 (1995).

Wainstein, M. A., et al., "CWR22: Androgen-Dependent Xenograft Model Derived from a Primary Human Prostatic Carcinoma," *Cancer Research*, 54:6049-6052 (1994).

Prellow, T. G., et al., "Xenografts of Primary Human Prostatic Carcinoma," *Journal of the National Cancer Institute*, 85(5):394-398 (1993).

Pretlow, T. G., et al., "Transplantation of Human Prostatic Carcinoma into Nude Mice in Matrigel," *Cancer Research*, 51:3814-3817 (1991).

Perez-Stable et al., *Cancer Research*, Vol. 57, Pages 900-906. (March 1, 1997).

Sato et al., *Journal of Urology*, Vol. 155: 5, Page 338A. (May 4, 1996).

TNT

van Weerden et al., *American Journal of Pathology*, Vol. 149: 3, Pages 1055-1062. (September 1996).

RECEIVED

~~MAY 13 2002~~

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE